Acrivon to Present Endometrial Cancer Data at ESGO Congress
Event summary
- Acrivon Therapeutics will present ACR-368 clinical data at ESGO 27th Annual Congress on February 27, 2026.
- Presentation focuses on Phase 2 study results for endometrial cancer patients selected by OncoSignature assay.
- Dr. Panagiotis Konstantinopoulos of Dana-Farber Cancer Institute will deliver the oral presentation.
- ACR-368 has received FDA Fast Track and Breakthrough Device designations for endometrial cancer treatment.
The big picture
Acrivon's presentation at ESGO comes as precision oncology continues to gain traction, with increasing focus on biomarker-driven patient selection. The company's proprietary AP3 platform represents a differentiated approach in the competitive oncology space, potentially offering more targeted treatment options for hard-to-treat cancers. The ESGO presentation provides a key validation opportunity for both ACR-368 and the broader platform technology.
What we're watching
- Clinical Validation
- How the ACR-368 data will position the drug in the competitive endometrial cancer treatment landscape.
- Regulatory Momentum
- Whether the positive data will accelerate FDA review timelines for potential approval.
- Pipeline Progress
- The pace at which Acrivon can advance its other pipeline candidates like ACR-2316 and ACR-6840.
Related topics